Activated protein C resistance testing for factor V Leiden

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1147-1150

  Kadauke, Stephan ^a   Khor, Bernard ^a   Van Cott, Elizabeth M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ANTITHROMBIN; ARGATROBAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; DABIGATRAN; HIRUDIN DERIVATIVE; HIRULOG; LUPUS ANTICOAGULANT; MORPHOLINE DERIVATIVE; PEPTIDE FRAGMENT; PIPECOLIC ACID DERIVATIVE; PROTEIN C; RECOMBINANT PROTEIN; RIVAROXABAN; THIOPHENE DERIVATIVE; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ACTIVATED PROTEIN C RESISTANCE ASSAY; ARTICLE; ASSAY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; GOOD LABORATORY PRACTICE; HUMAN; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADULT; ANALOGS AND DERIVATIVES; BIOASSAY; BLOOD; BLOOD CLOTTING TEST; CHEMISTRY; CHILD; FEMALE; LABORATORY DIAGNOSIS; METABOLISM; PREGNANCY; STANDARDS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BIOLOGICAL ASSAY; BLOOD COAGULATION TESTS; CHILD; FACTOR V; FACTOR XA; FALSE POSITIVE REACTIONS; FEMALE; HIRUDINS; HUMANS; LUPUS COAGULATION INHIBITOR; MORPHOLINES; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PREGNANCY; PROTEIN C; RECOMBINANT PROTEINS; THIOPHENES; WARFARIN;

EID: 84922393733     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23867     Document Type: Article

References (39)

1. Segers K, Dahlbäck B, Nicolaes GAF. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost 2007;98:530-542.
2. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506.
3. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
4. Greengard JS, Sun X, Xu X, et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-1362.
5. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343:1535-1536.
6. Zivelin A, Mor-Cohen R, Kovalsky V, et al. Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24, 000 years ago. Blood 2006;107:4666-4668.
7. Lindqvist PG, Zöller B, Dahlbäck B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden-an evolutionary advantage? Thromb Haemost 2001;86:1122-1123.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-1134.
9. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508.
11. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Clin Lab Med 2009;29:339-366.
12. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816.
13. Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 2007;131:890-901.
14. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002;126:1281-1295.
15. André E, Hacquard M, Alnot Y, et al. Activated protein C resistance test using factor VIII-deficient plasma: A new approach to the venous thrombotic risk? Thromb Haemost 2007;98:693-694.
16. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72:880-886.
17. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995;74:797-798.
18. Shaikh S, Van Cott EM. The effect of argatroban on activated protein C resistance. Am J Clin Pathol 2009;131:828-833.
19. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-139.
20. Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol, in press.
21. Quehenberger P, Handler S, Mannhalter C, et al. The Factor V (Leiden) test: Evaluation of an assay based on dilute Russell Viper Venom time for the detection of the Factor V Leiden mutation. Thromb Res 1999;96:125-133.
22. Wilmer M, Stocker C, Bühler B, et al. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay. Am J Clin Pathol 2004;122:836-842.
23. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-378.
24. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden: A review. Arch Pathol Lab Med 2007;131:866-871.
25. Strobl FJ, Hoffman S, Huber S, et al. Activated protein C resistance assay performance: Improvement by sample dilution with factor V-deficient plasma. Arch Pathol Lab Med 1998;122:430-433.
26. Sweeney JD, Blair AJ, King TC. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V(Leiden) (FVR506Q). Am J Clin Pathol 1997;108:74-77.
27. Zehnder JL, Benson RC. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 1996;106:107-111.
28. Trossaërt M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995;73:163-164.
29. Jorquera J, Montoro J, Fernández MA, et al. Modified test for activated protein C resistance. Lancet 1994;344:1162-1163.
30. Trossaërt M, Conard J, Horellou MH, et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996;75:521-522.
31. Rosen S, Andersson NE, Andersson M, et al. Modified COATEST (R) APC (TM) resistance assay including V-DEF plasma with a heparin antagonist: Analysis of heparin and OAC plasmas and influence of preanalytical variables. Blood Coagul Fibrinolys 1996;7:390. Poster presentation.
32. Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-109.
33. Saenz AJ, Johnson NV, Van Cott EM. Acquired activated protein C resistance caused by lupus anticoagulants. Am J Clin Pathol 2011;136:344-349.
34. Uttenreuther-Fischer MM, Ziemer S, Gaedicke G. Resistance to activated protein C (APCR): Reference values of APC-ratios for children. Thromb Haemost 1996;76:813-814.
35. Nowak-Göttl U, Kohlhase B, Vielhaber H, et al. APC resistance in neonates and infants: Adjustment of the APTT-based method. Thromb Res 1996;81:665-670.
36. Brandt G, Gruppo R, Glueck CJ, et al. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children. Thromb Haemost 1998;79:567-570.
37. Taylor LJ, Oster RA, Fritsma GA, et al. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden. Am J Clin Pathol 2008;129:494-499.
38. Prüller F, Weiss E-C, Raggam RB, et al. Activated protein C resistance assay and factor V Leiden. N Engl J Med 2014;371:685-686.
39. Van Cott EM. All that glitters is gold? Am J Hematol 2010;85:223-224.